http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : 정수지 ( Soo Jie Chung ) (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
한국인 음식물 의존성 운동유발 아나필락시스의 임상적 특성 분석
정수지 ( Soo Jie Chung ),심지수 ( Jisu Shim ),김형준 ( Hyung-jun Kim ),손경희 ( Kyoung-hee Sohn ),강성윤 ( Sung-yoon Kang ),강민규 ( Min-gyu Kang ),박한기 ( Han-ki Park ),강혜련 ( Hye-ryun Kang ) 대한천식알레르기학회 2016 Allergy Asthma & Respiratory Disease Vol.4 No.6
Purpose: Food-dependent exercise-induced anaphylaxis (FDEIA) is a rare subtype of food allergy in which both sensitization to food allergen and exercise as a trigger contribute to its development. However, its pathogenesis is still under investigation. This study compared clinical features, the causative foods, and the degree of sensitization to food between FDEIA and food anaphylaxis to characterize FDEIA more clearly. Methods: We retrospectively reviewed the medical records of patients who were diagnosed with FDEIA (n=89) or food anaphylaxis (n=115) between 2003 and 2015 at Seoul National University Hospital. Results: Subjects with FDEIA more frequently had urticaria than those with food anaphylaxis (88.8% vs. 76.5%, P=0.024). Whereas patients with FDEIA had less laryngeal edema than those with food anaphylaxis (12.4% vs. 30.4%, P=0.02). Wheat (67.4%) was the most common causative food allergen in FDEIA, whereas seafood (40.9%) was the most common culprit food allergen in food ana phylaxis. Also, subjects with FDEIA showed a lower atopic index score than those with food anaphylaxis (0.55±1.07 vs. 1.21±1.82, P=0.006). Conclusion: There were significant differences in clinical manifestation, causative food allergens and the degree of sensitization to food between FDEIA and food anaphylaxis. (Allergy Asthma Respir Dis 2016:4:436-441)
-
대한천식알레르기학회 알레르기비염 진료지침: 파트 2. 비약물치료의 업데이트
박상철 ( Sang Chul Park ),정수지 ( Soo Jie Chung ),최정희 ( Jeong-hee Choi ),이용주 ( Yong Ju Lee ),양현종 ( Hyeon-jong Yang ),박도양 ( Do-yang Park ),김동규 ( Dong-kyu Kim ),이일환 ( Il Hwan Lee ),김수환 ( Soo Whan Kim ),김도현 ( 대한천식알레르기학회 2023 Allergy Asthma & Respiratory Disease Vol.11 No.3
Allergic rhinitis is the most common chronic disease worldwide. Various upper airway symptoms lower quality of life, and due to the recurrent symptoms, multiple treatments are usually attempted rather than one definitive treatment. There are alternatives to medi cal (medication-based) and nonmedical treatments. A guideline is needed to understand allergic rhinitis and develop an appropri ate treatment plan. We have developed guidelines for medical treatment based on previous reports. The current guidelines herein are associated with the “KAAACI Evidence-Based Guidelines for Allergic Rhinitis in Korea, Part 1: Update in pharmacotherapy” in which we aimed to provide evidence-based recommendations for the medical treatment of allergic rhinitis. Part 2 focuses on non pharmacological management, including allergen-specific immunotherapy, subcutaneous or sublingual immunotherapy, nasal sa line irrigation, environmental management strategies, companion animal management, and nasal turbinate surgery. The evidence to support the treatment efficacy, safety, and selection has been systematically reviewed. However, larger controlled studies are needed to elevate the level of evidence to select rational non-medical therapeutic options for patients with allergic rhinitis. (Allergy Asthma Respir Dis 2023;11:126-134)
-
Cetuximab에 의한 아나필락시스를 보인 환자에서 성공적인 탈감작 적용 1예
원하경 ( Ha Kyeong Won ),문성도 ( Sung Do Moon ),심지수 ( Ji Su Shim ),정수지 ( Soo Jie Chung ),김건우 ( Gun Woo Kim ),김수정 ( Su Jeong Kim ),박한기 ( Han Ki Park ),강혜련 ( Hye Ryun Kang ) 대한천식알레르기학회 2015 Allergy Asthma & Respiratory Disease Vol.3 No.4
Cetuximab, a chimeric mouse-human immunoglobulin, is an antiepidermal growth factor receptor monoclonal antibody. It has been approved by the U.S. Food and Drug Administration for the treatment of metastatic colorectal and head/neck cancer, but can cause fatal hypersensitivity reactions in some patients. A 66-year-old male with metastatic sigmoid cancer had cetuximab-induced anaphylaxis when the first dose of cetuximab was administered. Cetuximab was safely readministered for another 15 cycles based on the rapid desensitization protocol. We experienced a case of cetuximab-induced anaphylaxis on the first exposure which was successfully managed by rapid desensitization. (Allergy Asthma Respir Dis 2015;3:294-296)
KCI
KISS연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
